AARTIPHARM · NSE
Aarti Pharmalabs Limited
₹820.4
-0.79% (-₹6.55)
Prev. close
₹826.95
Volume
19,01,494
Delivery %
63.2%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, ophthalmologic, antidepressant medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates, such as xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. It serves pharmaceutical, nutraceutical, and beverage industries. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Hetal Gogri Gala
Headquarters
Mumbai
Employees
2,421
Website
aartipharmalabs.comExchange
View on NSE ↗Key stats
Market cap
₹7,439.37 Cr
P/E ratio (TTM)
36.3
Dividend yield
0.48%
EPS (TTM)
₹22.58
Beta (1Y · daily vs NIFTY 50)
1.17
Beta (5Y · monthly vs NIFTY 50)
0.96
Shares float
4.93 Cr
EPS · quarter ended Jun 2026
₹8.39
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide. EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹1,945.23 Cr | ₹1,852.61 Cr | ₹2,086.00 Cr | ₹1,819.44 Cr | |
| EBITDA | — | — | ₹344.36 Cr | ₹390.94 Cr | ₹474.49 Cr | ₹384.16 Cr |
| ₹0 | ₹122.00 Cr | ₹193.49 Cr | ₹216.90 Cr | ₹272.40 Cr | ₹174.71 Cr | |
| Diluted EPS | — | — | ₹21.35 | ₹23.93 | ₹30.04 | ₹19.25 |
Revenue, Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Tax provision, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹0 | ₹2,039.90 Cr | ₹2,244.00 Cr | ₹2,582.00 Cr | ₹2,906.00 Cr | ₹3,482.00 Cr | |
| — | ₹341.06 Cr | ₹215.31 Cr | ₹285.25 Cr | ₹420.82 Cr | ₹769.36 Cr | |
| Stockholders' equity | ₹25.00 L | ₹1,386.48 Cr | ₹1,558.00 Cr | ₹1,757.00 Cr | ₹1,990.00 Cr | ₹2,124.00 Cr |
Current assets, Inventory, Receivables (trade + unbilled), Trade receivables, Unbilled receivables (contract assets), Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹0 | ₹44.00 Cr | ₹250.00 Cr | ₹216.00 Cr | ₹332.00 Cr | ₹262.00 Cr | |
| Investing cash flow | — | — | ₹-157.80 Cr | ₹-214.57 Cr | ₹-412.48 Cr | ₹-430.72 Cr |
| ₹0 | ₹260.00 Cr | ₹-163.00 Cr | ₹10.00 Cr | ₹65.00 Cr | ₹171.00 Cr | |
| Capital expenditure | — | — | ₹-119.66 Cr | ₹-198.79 Cr | ₹-443.88 Cr | ₹-448.31 Cr |
| End cash position | — | — | ₹12.12 Cr | ₹23.64 Cr | ₹6.73 Cr | ₹8.53 Cr |
Change in working capital, Investing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Jan 23 | Mar 23–Jun 23(2Q) | Sep 23 | Dec 23–Jun 24(3Q) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.16% | 45.98% | 46.30% | 46.46% | 46.10% | 44.66% | 44.29% | 43.72% | 42.88% | 43.10% | 43.08% | 42.86% |
| Public | 55.84% | 54.02% | 53.70% | 53.54% | 53.90% | 55.34% | 55.71% | 56.28% | 57.12% | 56.90% | 56.92% | 57.14% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aarti Pharmalabs Limited | ₹7,372.27 Cr | ₹826.95 | 36.0 | 3.47 | 8.2% | 0.36 | -14.3% | -10.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Show all 12
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.